Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

Cited by (983)

Items 101–200 of 983

1. Cell fate regulation governed by p53: Friends or reversible foes in cancer therapy
   Bin Song, Ping Yang, Shuyu Zhang · 2024 · 癌症：英文版
2. Tumor mutational burden in lung cancer: a systematic literature review
   Connor Willis, Michelle Fiander, Dao Tran, Beata Korytowsky, John-Michael Thomas, Florencio Calderon, Teresa Maria Zyczynski, Diana I Brixner, David Dean Stenehjem · 2019 · Oncotarget
3. Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade
   Yanna Lei, Xiaoying Li, Qian Huang, Xiufeng Zheng, Ming Liu · 2021 · Frontiers in Oncology
4. VISTA expression associated with CD8 confers a favorable immune microenvironment and better overall survival in hepatocellular carcinoma
   Ming Zhang, Huajin Pang, Wei Zhao, Yufa Li, Li‐Xu Yan, Zhong‐Yi Dong, Xiaofeng He · 2018 · BMC Cancer
5. Resistance to immune checkpoint inhibitors in non-small cell lung cancer: biomarkers and therapeutic strategies
   Robert John Walsh, Ross Andrew Soo · 2020 · Therapeutic Advances in Medical Oncology
6. The role of p53 in anti-tumor immunity and response to immunotherapy
   Lindsey Carlsen, Shengliang Zhang, Xiaobing Tian, Arielle De La Cruz, Andrew George, Taylor E. Arnoff, Wafik S. El‐Deiry · 2023 · Frontiers in Molecular Biosciences
7. Unveiling the role of KRAS in tumor immune microenvironment
   Miao Xu, Xing Zhao, Ti Wen, Xiujuan Qu · 2024 · Biomedicine & Pharmacotherapy
8. Association ofMUC16Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors
   Lei Zhang, Xiaohong Han, Yuankai Shi · 2020 · JAMA Network Open
9. The Resistance Mechanisms of Lung Cancer Immunotherapy
   Fen Wang, Shubin Wang, Qing Hua Zhou · 2020 · Frontiers in Oncology
10. Kras and tumor immunity: friend or foe?
    Cullis, Jane, Das, Shipra, Bar-Sagi, Dafna · 2018 · Cold Spring Harbor Perspectives in Medicine
11. BRCA1/2 and TP53 mutation status associates with PD-1 and PD-L1 expression in ovarian cancer
    Verena E. Wieser, Inge Gaugg, Martina Fleischer, Giridhar Shivalingaiah, Soeren Wenzel, Susanne Sprung, Sigurd Lax, Alain Gustave Zeimet, Heidi Fiegl, Christian Marth · 2018 · Oncotarget
12. Identification of an Immune Signature Predicting Prognosis Risk and Lymphocyte Infiltration in Colon Cancer
    Xinyu Li, Dacheng Wen, Xiaokang Li, Chunli Yao, Wei Chong, Hao Chen · 2020 · Frontiers in Immunology
13. Clinical relevance of PD-L1 expression and CD8 T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer
    Liu, Si-yang, Dong, Zhong-yi, Wu, Si-pei, Xie, Zhi, Yan, Li-xu, Li, Yu-Fa, Yan, Hong-hong, Su, Jian, Yang, Jin-Ji, Zhou, Qing et al. · 2018 · Lung Cancer
14. Clinical and Recent Patents Applications of PD-1/PD-L1 Targeting Immunotherapy in Cancer Treatment—Current Progress, Strategy, and Future Perspective
    Libin Guo, Ran Wei, Yao Lin, Hang Fai Kwok · 2020 · Frontiers in Immunology
15. Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations
    Passiglia, Francesco, Cappuzzo, Federico, Alabiso, Oscar, Bettini, Anna Cecilia, Bidoli, Paolo, Chiari, Rita, Defferrari, Carlotta, Delmonte, Angelo, Finocchiaro, Giovanna, Francini, Guido et al. · 2019 · British Journal of Cancer
16. Lipid Metabolism Regulates Oxidative Stress and Ferroptosis in RAS-Driven Cancers: A Perspective on Cancer Progression and Therapy
    Caterina Bartolacci, Cristina Andreani, Yasmin Elgammal, Pier Paolo Scaglioni · 2021 · Frontiers in Molecular Biosciences
17. Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response
    Qingyang Xiao, André Nobre, Pilar Piñeiro, Miguel‐Ángel Berciano‐Guerrero, Emilio Alba, Manuel Cobo, Volker Martin Lauschke, Isabel Barragán · 2020 · Journal of Clinical Medicine
18. Short-Chain Fatty Acids: A Soldier Fighting Against Inflammation and Protecting From Tumorigenesis in People With Diabetes
    Qiyu Yang, Jing Ouyang, Fengjun Sun, Jiadan Yang · 2020 · Frontiers in Immunology
19. Intratumor heterogeneity: the hidden barrier to immunotherapy against MSI tumors from the perspective of IFN-γ signaling and tumor-infiltrating lymphocytes
    Wantao Wu, Yihan Liu, Shan Zeng, Ying Han, Hong Shen · 2021 · Journal of Hematology & Oncology
20. Impact of PD-L1 expression, driver mutations and clinical characteristics on survival after anti-PD-1/PD-L1 immunotherapy versus chemotherapy in non-small-cell lung cancer: A meta-analysis of randomized trials
    Qingyuan Huang, Hua Zhang, Josephine Hai, Mark A. Socinski, Eric Kian Saik Lim, Haiquan Chen, Justin Stebbing · 2017 · OncoImmunology
21. Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies
    Hongxing Shen, Eddy Shih-Hsin Yang, M. Conry, John B. Fiveash, Carlo M. Contreras, James A. Bonner, Lewis Z. Shi · 2019 · Genes & Diseases
22. Rise of the natural red pigment ‘prodigiosin’ as an immunomodulator in cancer
    Mohammed Moustapha Anwar, Chris Albanese, Nadia Μ. Hamdy, Ahmed S. Sultan · 2022 · Cancer Cell International
23. Correlation between lower balance of Th2 helper T-cells and expression of PD-L1/PD-1 axis genes enables prognostic prediction in patients with glioblastoma
    Yasuo Takashima, Atsushi Kawaguchi, Tomohiko Kanayama, Azusa Hayano, Ryuya Yamanaka · 2018 · Oncotarget
24. KRAS in NSCLC: State of the Art and Future Perspectives
    Cascetta, Priscilla, Marinello, Arianna, Lazzari, Chiara, Gregorc, Vanesa, Planchard, David, Bianco, Roberto, Normanno, Nicola, Morabito, Alessandro · 2022 · Cancers
25. TP53 Mutation as Potential Negative Predictor for Response of Anti-CTLA-4 Therapy in Metastatic Melanoma
    Wenjing Xiao, Nan Du, Taoyuan Huang, Jinan Guo, Xingkui Mo, Tao Yuan, Yong Chen, Ting Ye, C. Xu, Wenxian Wang et al. · 2018 · EBioMedicine
26. DNA Repair Gene Mutations as Predictors of Immune Checkpoint Inhibitor Response beyond Tumor Mutation Burden
    David Hsiehchen, Antony Hsieh, Robert M. Samstein, Tianshi Lu, Muhammad Shaalan Beg, David E. Gerber, Tao Wang, Luc G.T. Morris, Hao Zhu · 2020 · Cell Reports Medicine
27. Prediction of biomarkers and therapeutic combinations for anti-PD-1 immunotherapy using the global gene network association
    Chia-Chin Wu, Yanru Wang, John Andrew Livingston, Jianhua Zhang, P. Andrew Futreal · 2022 · Nature Communications
28. Escape from T-cell–targeting immunotherapies in acute myeloid leukemia
    Jayakumar Narayanan Vadakekolathu, Sergio Rutella · 2023 · Blood
29. Association between PD-L1 expression and driver gene status in non-small-cell lung cancer: a meta-analysis
    Bo Lan, Chengxi Ma, Chengyan Zhang, Shoujie Chai, Pingli Wang, Liren Ding, Kai Wang · 2018 · Oncotarget
30. p53 at the crossroads of tumor immunity
    Gizem Efe, Anil K. Rustgi, Carol L. Prives · 2024 · Nature Cancer
31. KRAS G12D mutation predicts lower TMB and drives immune suppression in lung adenocarcinoma
    Gao, Ge, Liao, Weiting, Ma, Qizhi, Zhang, Benxia, Chen, Yue, Wang, Yongsheng · 2020 · Lung Cancer
32. The Activity of Immune Checkpoint Inhibition in KRAS Mutated Non-small Cell Lung Cancer: A Single Centre Experience
    Javier Torralvo, Alex Friedlaender, Vérane Achard, Alfredo Addeo · 2019 · Cancer Genomics & Proteomics
33. KEAP1 and TP53 Frame Genomic, Evolutionary, and Immunologic Subtypes of Lung Adenocarcinoma With Different Sensitivity to Immunotherapy
    Stefano Scalera, Marco Mazzotta, Giacomo Corleone, Francesca Sperati, Irene Terrenato, Eriseld Krasniqi, Laura Pizzuti, Maddalena Barba, Patrizia Vici, Enzo Gallo et al. · 2021 · Journal of Thoracic Oncology
34. Current and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies?
    Simon Garinet, Pierre Laurent‐Puig, Hélène Blons, Jean‐Baptiste Oudart · 2018 · Journal of Clinical Medicine
35. Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non-small cell lung cancer patients
    Si‐Yang Maggie Liu, Hao Sun, Jiaying Zhou, Guang‐Ling Jie, Zhi Xie, Yang Washington Shao, Xian Zhang, Junyi Ye, Chunxiang Chen, Xu‐Chao Zhang et al. · 2020 · Biomarker Research
36. KRAS as a Modulator of the Inflammatory Tumor Microenvironment: Therapeutic Implications
    Flávia Dayana Silva Pereira, A I Ferreira, Celso Albuquerque Reis, Maria João Sousa, María José Oliveira, Ana Preto · 2022 · Cells
37. An artificial intelligence network‐guided signature for predicting outcome and immunotherapy response in lung adenocarcinoma patients based on 26 machine learning algorithms
    Nan Zhang, Hao Zhang, Zaoqu Liu, Ziyu Dai, Wantao Wu, Ran Zhou, Shuyu Li, Zeyu Wang, Xisong Liang, Jie Wen et al. · 2023 · Cell Proliferation
38. E3 ubiquitin ligases Cbl‐b and c‐Cbl downregulate PD ‐L1 in EGFR wild‐type non‐small cell lung cancer
    Shuo Wang, Ling Xu, Xiaofang Che, Ce Li, Lu Xu, Kezuo Hou, Yibo Fan, Ti Wen, Xiujuan Qu, Yunpeng Liu · 2018 · FEBS Letters
39. Differential Immune-Related Microenvironment Determines Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Blockade Efficacy in Patients With Advanced NSCLC
    Masayuki Shirasawa, Tatsuya Yoshida, Yukiko Shimoda, Daisuke Takayanagi, Kouya Shiraishi, Takashi Kubo, Sachiyo Mitani, Yuji Matsumoto, Ken Masuda, Yuki Shinno et al. · 2021 · Journal of Thoracic Oncology
40. CDK4/6 inhibition triggers ICAM1-driven immune response and sensitizes LKB1 mutant lung cancer to immunotherapy
    Xue Bai, Ze-Qin Guo, Yan-Pei Zhang, Zhenzhen Fan, Lijuan Liu, Li Liu, Li-Li Long, Si-Cong Ma, Jian Wang, Yuan Fang et al. · 2023 · Nature Communications
41. TP53/mTORC1-mediated bidirectional regulation of PD-L1 modulates immune evasion in hepatocellular carcinoma
    Jiong-Jie Yu, Sunbin Ling, Jiachen Hong, Lincheng Zhang, Wei Zhou, Lu Yin, Shengjun Xu, Qingyang Que, Yongfeng Wu, Qifan Zhan et al. · 2023 · Journal for ImmunoTherapy of Cancer
42. Molecular markers and prediction of response to immunotherapy in non-small cell lung cancer, an update
    Hélène Blons, Simon Garinet, Pierre Laurent‐Puig, Jean‐Baptiste Oudart · 2019 · Journal of Thoracic Disease
43. Racial differences in characteristics and prognoses between Asian and white patients with nonsmall cell lung cancer receiving atezolizumab: An ancillary analysis of the POPLAR and OAK studies
    Jie Qian, Wei Nie, Jun Lü, Lele Zhang, Yanwei Zhang, Bo Zhang, Shuyuan Wang, Minjuan Hu, Jianlin Xu, Yuqing Lou et al. · 2019 · International Journal of Cancer
44. Immunotherapy in non-small cell lung cancer: update and new insights
    Xabier Mielgo-Rubio, Eider Azkona Uribelarrea, Laura Quintanta Cortés, M. Sereno Moyano · 2021 · Journal of Clinical and Translational Research
45. Spatial and Temporal Changes in PD-L1 Expression in Cancer: The Role of Genetic Drivers, Tumor Microenvironment and Resistance to Therapy
    Elena Shklovskaya, Helen Rizos · 2020 · International Journal of Molecular Sciences
46. Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC: Results From the European Thoracic Oncology Platform Lungscape Project
    Stephen P. Finn, Alfredo Addeo, Urania G. Dafni, Erik Thunnissen, Lukas Bubendorf, Line Bille Madsen, Wojciech Biernat, Eric K. Verbeken, Javier Hernández‐Losa, Antonio Marchetti et al. · 2021 · Journal of Thoracic Oncology
47. The Mechanisms of PD-L1 Regulation in Non-Small-Cell Lung Cancer (NSCLC): Which Are the Involved Players?
    Giuseppe Lamberti, Monia Sisi, Elisa Andrini, Arianna Palladini, Francesca Giunchi, Pier‐Luigi Lollini, Andrea Ardizzoni, Francesco Gelsomino · 2020 · Cancers
48. A TP53-Associated Immune Prognostic Signature for the Prediction of Overall Survival and Therapeutic Responses in Muscle-Invasive Bladder Cancer
    Xiangkun Wu, Daojun Lv, Chao Cai, Zhijian Zhao, Ming Wang, Wenzhe Chen, Yongda Liu · 2020 · Frontiers in Immunology
49. KRASG12C/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (≥50%) lung adenocarcinoma
    Frost, Nikolaj, Kollmeier, Jens, Vollbrecht, Claudia, Grah, Christian, Matthes, Burkhard, Pultermann, Dennis, von Laffert, Maximilian, Lüders, Heike, Olive, Elisabeth, Raspe, Matthias et al. · 2021 · Translational Lung Cancer Research
50. KRAS/LKB1 and KRAS/TP53 co-mutations create divergent immune signatures in lung adenocarcinomas
    Meichen Gu, Tiankai Xu, Pengyu Chang · 2021 · Therapeutic Advances in Medical Oncology
51. Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies
    Anne-Laure Désage, Camille Léonce, Aurélie Swalduz, Sandra Ortiz‐Cuaran · 2022 · Frontiers in Oncology
52. Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer
    Sara Elena Rebuzzi, Lodovica Zullo, Giovanni Rossi, Massimiliano Grassi, Veronica Murianni, Marco Tagliamento, Arsela Prelaj, Simona Coco, Luca Longo, Maria Giovanna Dal Bello et al. · 2021 · International Journal of Molecular Sciences
53. Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort study
    Xue Bai, Dehua Wu, Si-Cong Ma, Jian Wang, Xin-Ran Tang, Shuai Kang, Qiang John Fu, Chuanhui Cao, He-San Luo, Yuhan Chen et al. · 2020 · Journal for ImmunoTherapy of Cancer
54. Life and Death Decision-Making by p53 and Implications for Cancer Immunotherapy
    Yong U. Liu, Patrick L. Leslie, Yanping Zhang · 2020 · Trends in cancer
55. Immune microenvironment features and efficacy of PD‐1/PD‐L1 blockade in non‐small cell lung cancer patients with EGFR or HER2 exon 20 insertions
    Kaiyan Chen, Guoqiang Pan, Guoping Cheng, Fanrong Zhang, Yanjun Xu, Zhiyu Huang, Yun Fan · 2020 · Thoracic Cancer
56. VISTA expression and patient selection for immune-based anticancer therapy
    Alexander Stephen Martin, Michael Molloy, Andrey V. Ugolkov, Reinhard W. Von Roemeling, Randolph J. Noelle, Lionel D. Lewis, Melissa Lynne Johnson, Laszlo George Radvanyi, Robert E. Martell · 2023 · Frontiers in Immunology
57. SMARCA4 mutations in KRAS ‐mutant lung adenocarcinoma: a multi‐cohort analysis
    Liang Liu, Tamjeed Ahmed, William Jeffrey Petty, Stefan C. Grant, Jimmy Ruiz, Thomas William Lycan, Ümit Topaloĝlu, Ping‐Chieh Chou, Lance David Miller, Gregory A. Hawkins et al. · 2020 · Molecular Oncology
58. Cancer vaccines: Targeting KRAS-driven cancers
    Ying Zhang, Jinan Ma, Hai-Xia Zhang, Yu‐Na Jiang, Wenhao Luo · 2020 · Expert Review of Vaccines
59. Genetic and Immune Profiles of Solid Predominant Lung Adenocarcinoma Reveal Potential Immunotherapeutic Strategies
    Zhong‐Yi Dong, Chao Zhang, Yufa Li, Jian Su, Zhi Xie, Si‐Yang Maggie Liu, Li‐Xu Yan, Zhihong Chen, Xue‐Ning Yang, Jun‐Tao Lin et al. · 2017 · Journal of Thoracic Oncology
60. Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in Taiwan
    Shu‐Yung Lin, Ching‐Yao Yang, Bin-Chi Liao, Chao‐Chi Ho, Wei‐Yu Liao, Kuan‐Yu Chen, Tzu-Hsiu Tsai, Chia‐Lin Hsu, Wei‐Hsun Hsu, Kang‐Yi Su et al. · 2018 · Journal of Cancer
61. High TGF-β signature predicts immunotherapy resistance in gynecologic cancer patients treated with immune checkpoint inhibition
    Ying Ni, Ahmed S. A. Soliman, Amy S Joehlin-Price, Peter Graham Rose, Anda Vlad, Robert P. Edwards, Haider Mahdi · 2021 · npj Precision Oncology
62. Fusobacterium is enriched in oral cancer and promotes induction of programmed death-ligand 1 (PD-L1)
    Chieko Michikawa, Vancheswaran Gopalakrishnan, Amani M. Harrandah, Tatiana V. Karpinets, Rekha Rani Garg, Randy Aaron Chu, Yuk Pheel Park, Sasanka S. Chukkapallia, Nikhita Yadlapalli, Kelly Erikson et al. · 2022 · Neoplasia
63. EPHA5 mutation predicts the durable clinical benefit of immune checkpoint inhibitors in patients with lung adenocarcinoma
    Weimei Huang, Anqi Lin, Peng Luo, Yuchen Liu, Wentao Xu, Weiliang Zhu, Ting Wei, Qingwen Lyu, Linlang Guo, Jian Zhang · 2020 · Cancer Gene Therapy
64. KRAS Mutation Subtypes and Their Association with Other Driver Mutations in Oncogenic Pathways
    Koushik Mondal, Mahesh Kumar Posa, Revathi Panduranga Shenoy, Susanta Roychoudhury · 2024 · Cells
65. Immunotherapy in the Asiatic population: any differences from Caucasian population?
    Lun-Xi Peng, Yi-Long Lung Cancer Wu · 2018 · Journal of Thoracic Disease
66. New advances in immunotherapy for non-small cell lung cancer.
    Haifeng Qin, Fang Wang, Hui Liu, Zhen Zeng, Shasha Wang, Xin Hui Pan, Hongjun Gao · 2018 · Europe PMC (PubMed Central)
67. Targeting KRAS-Mutant Non–Small-Cell Lung Cancer: One Mutation at a Time, With a Focus on KRAS G12C Mutations
    Timothy Francis Burns, Hossein Borghaei, Suresh S. Ramalingam, Tony S.K. Mok, Solange Peters · 2020 · Journal of Clinical Oncology
68. Comprehensive analysis of POLE and POLD1 Gene Variations identifies cancer patients potentially benefit from immunotherapy in Chinese population
    Jianfei Yao, Yuan Gong, Wei Zhao, Zhifeng Han, Shaohua Guo, Hongyi Liu, Xiumei Peng, Wenhua Xiao, Yuemin Li, Shiying Dang et al. · 2019 · Scientific Reports
69. Driver mutations of intrahepatic cholangiocarcinoma shape clinically relevant genomic clusters with distinct molecular features and therapeutic vulnerabilities
    Xiangyu Wang, Wenwei Zhu, Zheng Wang, Jian-Bo Huang, Shenghao Wang, Fumao Bai, Tian‐En Li, Ying Zhu, Jing Zhao, Xin Yang et al. · 2021 · Theranostics
70. Systematic pan-cancer analysis of mutation–treatment interactions using large real-world clinicogenomics data
    Ruishan Liu, Shemra Rizzo, Sarah Waliany, Marius Rene Garmhausen, Navdeep Pal, Zhi Huang, Nayan Chaudhary, Lisa E. Wang, Chris G. Harbron, Joel W. Neal et al. · 2022 · Nature Medicine
71. Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors
    Paul van der Leest, Birgitta I. Hiddinga, Anneke Miedema, Maria L. Aguirre Azpurua, Naomi Rifaela, Arja ter Elst, Wim Timens, Harry J.M. Groen, Léon C.L.T. van Kempen, T. Jeroen N. Hiltermann et al. · 2021 · Molecular Oncology
72. TP53 Co-Mutations in Advanced EGFR-Mutated Non–Small Cell Lung Cancer: Prognosis and Therapeutic Strategy for Cancer Therapy
    Surui Liu, Jin Seok Yu, Hui Zhang, Jie Liu · 2022 · Frontiers in Oncology
73. Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1–High (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer
    Philip Bischoff, Martin Reck, Tobias Raphael Overbeck, Petros Christopoulos, Achim Rittmeyer, H Lüders, Jens Kollmeier, Jonas Kulhavy, Marcel Kemper, Niels Reinmuth et al. · 2023 · Journal of Thoracic Oncology
74. Identification of molecular features correlating with tumor immunity in gastric cancer by multi-omics data analysis
    Yin He, Xiaosheng Wang · 2020 · Annals of Translational Medicine
75. Potent immunogenicity in BRCA 1 ‐mutated patients with high‐grade serous ovarian carcinoma
    Ying Dai, Chengdu Sun, Yi Feng, Qingzhu Jia, Bo Zhu · 2018 · Journal of Cellular and Molecular Medicine
76. Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis
    Jun Zhou, Yongkun Sun, Wen Zhang, Jiajia Yuan, Zhi Peng, Wei Wang, Jifang Gong, Lin Yang, Yanshuo Cao, Hong Zhao et al. · 2022 · Hepatology
77. Prognostic Biomarker TP53 Mutations for Immune Checkpoint Blockade Therapy and Its Association With Tumor Microenvironment of Lung Adenocarcinoma
    Xinqing Lin, Liqiang Wang, Xiaohong Xie, Yinyin Qin, Zhanhong Xie, Ming Ouyang, Chengzhi Zhou · 2020 · Frontiers in Molecular Biosciences
78. Age and Mutations as Predictors of the Response to Immunotherapy in Head and Neck Squamous Cell Cancer
    Yueming Zhang, Anqi Lin, Yonghe Li, Weimin Ding, Hui Meng, Peng Luo, Jian Zhang · 2020 · Frontiers in Cell and Developmental Biology
79. TOX correlates with prognosis, immune infiltration, and T cells exhaustion in lung adenocarcinoma
    Longbin Guo, Xuanzi Li, Rongping Liu, Yulei Chen, Chen Ren, Shasha Du · 2020 · Cancer Medicine
80. Genomic landscape and prognosis of patients with TP53-mutated non-small cell lung cancer
    Zhisong Fan, Qi Zhang, Feng Li, Long Wang, Xinliang Zhou, Jing Han, Dan Li, Jiayin Liu, Xue Zhang, Jing Zuo et al. · 2022 · Annals of Translational Medicine
81. Association of PTPRT mutations with immune checkpoint inhibitors response and outcome in melanoma and non‐small cell lung cancer
    Wenjing Zhang, Fuyan Shi, Yujia Kong, Yuting Li, Chao Sheng, Suzhen Wang, Qinghua Wang · 2021 · Cancer Medicine
82. Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients’ selection
    Giuseppe Luigi Banna, Francesco Passiglia, Francesca Colonese, Stefania Canova, Jessica Menis, Alfredo Addeo, Antonio Dello Russo, Diego Luigi Cortinovis · 2018 · Critical Reviews in Oncology/Hematology
83. Checkpoint blockade‐based immunotherapy in the context of tumor microenvironment: Opportunities and challenges
    Jingjing Duan, Yu Wang, Shunchang Jiao · 2018 · Cancer Medicine
84. KRAS G12V mutation upregulates PD‐L1 expression via TGF‐β/EMT signaling pathway in human non‐small‐cell lung cancer
    Lina Pan, Yun‐Fang Ma, Zhen Li, Jia‐An Hu, Zhihong Xu · 2020 · Cell Biology International
85. Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors
    Alice Indini, Erika Rijavec, Michele Ghidini, Alessio Cortellini, Francesco Grossi · 2021 · Pharmaceutics
86. Cancer genome and tumor microenvironment: Reciprocal crosstalk shapes lung cancer plasticity
    Siavash Mansouri, Daniel Heylmann, Thorsten Stiewe, Michael Kracht, Rajkumar Savai · 2022 · eLife
87. An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer
    Clara Mayo‐de‐las‐Casas, Mónica Garzón‐Ibáñez, Núria Jordana‐Ariza, Beatriz García‐Peláez, Ariadna Balada‐Bel, Sergi Villatoro, Umberto Malapelle, Niki Karachaliou, Giancarlo Troncone, Rafael Rosell et al. · 2017 · Expert Review of Molecular Diagnostics
88. Targeting the Tumor Microenvironment: An Unexplored Strategy for Mutant KRAS Tumors
    Patrícia Dias Carvalho, Ana Luísa Machado, Flávia Martins, Raquel Seruca, Sérgia Velho · 2019 · Cancers
89. Role of immunotherapy and co-mutations on KRAS-mutant non- small cell lung cancer survival
    Idoroenyi Usua Amanam, Isa Mambetsariev, Rohan Gupta, Srisairam Achuthan, Yingyu Wang, Rebecca R. Pharaon, Erminia Massarelli, Marianna Koczywas, Karen L. Reckamp, Ravi Salgia · 2020 · Journal of Thoracic Disease
90. TP53 somatic mutations are associated with poor survival in non-small cell lung cancer patients who undergo immunotherapy
    Liqin Zhao, Xiaofei Qu, Zhenhua Wu, Yuehua Li, Xiaowei Zhang, Weijian Guo · 2020 · Aging
91. P53-regulated miR-320a targets PDL1 and is downregulated in malignant mesothelioma
    Caterina Costa, Paola Indovina, Eliseo Mattioli, Iris Maria Forte, Carmelina Antonella Iannuzzi, Luca Luzzi, Cristiana Bellan, Simona De Summa, Enrico M Bucci, Domenico Di Marzo et al. · 2020 · Cell Death and Disease
92. A Review of the Clinical Characteristics and Novel Molecular Subtypes of Endometrioid Ovarian Cancer
    Shuangfeng Chen, Yuebo Li, Lili Qian, Sisi Deng, Luwen Liu, Weihua Xiao, Ying Yin Zhou · 2021 · Frontiers in Oncology
93. A potential treatment option for transformed small-cell lung cancer on PD-L1 inhibitor-based combination therapy improved survival
    Chanyuan Zhang, Hao Sun, Junwei Su, Yuqing Chen, Shiling Zhang, Ming-Ying Zheng, Yufa Li, Jie Huang, Chao Zhang, Zaixian Tai et al. · 2022 · Lung Cancer
94. Joint inference of exclusivity patterns and recurrent trajectories from tumor mutation trees
    Xiang Ge Luo, Jack Kuipers, Niko Beerenwinkel · 2023 · Nature Communications
95. Immunotherapy resistance in solid tumors: mechanisms and potential solutions
    Daniel S. Lefler, Steven Anthony Manobianco, Babar Bashir · 2024 · Cancer Biology & Therapy
96. LRP1B or TP53 mutations are associated with higher tumor mutational burden and worse survival in hepatocellular carcinoma
    Longrong Wang, Kai Yan, Xigan He, Hongxu Zhu, Jia Song, Shiqing Chen, Shangli Cai, Yiming Zhao, Lu Wang · 2020 · Journal of Cancer
97. On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma
    Colin R. Lindsay, Marina Chiara Garassino, Ernest Nadal, Katarina Öhrling, Matthias Scheffler, Julien Mazières · 2021 · Lung Cancer
98. More to the RAS Story: KRAS ^G12C Inhibition, Resistance Mechanisms, and Moving Beyond KRAS ^G12C
    Lietman, Caressa D., Johnson, Melissa L., McCormick, Frank, Lindsay, Colin R. · 2022 · American Society of Clinical Oncology Educational Book
99. Multi-omics and artificial intelligence predict clinical outcomes of immunotherapy in non-small cell lung cancer patients
    Ting Mei, Ting Wang, Qinghua Zhou · 2024 · Clinical and Experimental Medicine
100. Understanding the Complexity of the Tumor Microenvironment in K-ras Mutant Lung Cancer: Finding an Alternative Path to Prevention and Treatment
     Shanshan Deng, Michael J. Clowers, Walter V. Velasco, Marco A. Ramos-Castaneda, Seyed Javad Moghaddam · 2020 · Frontiers in Oncology